US court dismisses infringement, allows trade secret theft claims against Nevro
28-11-2019
Pavel Kapysh / Shutterstock.com
The US Federal Trade Commission is requiring medical device maker Boston Scientific to divest business, as part of a settlement resolving antitrust charges related to its acquisition of UK-based healthcare company BTG.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Boston Scientific, BTG, FTC, antitrust, mergers & acquisitions, medical device manufacture, healthcare, oncology, drug eluting beads, competition